Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Drug Screening Assays, Antitumor × Clear all
NCT05833802 2023-04-27

Computation Prediction of Drug Response Based on Omics Data

Peking University Cancer Hospital & Institute

Unknown
25 enrolled
Breast

Breast Neoplasms

NCT00003253 2013-12-19

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡